Peculiarities of the COVID-19 course and consequences in overweight and obese patients. Lessons from the current pandemic
https://doi.org/10.14341/omet12663
Abstract
Treatment difficulties of COVID-19 have determined the need to identify predictive risk factors for the development of a complicated disease course, critical conditions and death. Endocrine and metabolic abnormalities associated with obesity, including impaired insulin sensitivity, chronic inflammation and impaired lipid and fatty acid metabolism, increase immunological dysregulation and make these patients more susceptible to developing infectious diseases. Research data allows us to single out obesity as a risk factor for the aggravated course of COVID-19, as well as a longer period before the virus elimination, and, therefore, the risk of virus transmission. Potentiation of cardiovascular risk factors, an increase in the production of pro-inflammatory cytokines, coagulopathy are factors in the development of unfavorable outcomes in such patients.This review presents literature data on the features of the course and the mechanisms of development of complications in patients with new coronavirus infection and obesity. Taking into account the need to restore metabolic health to increase the adaptive and resistant capacities of the body in the face of the threat of a new increase in the prevalence of COVID-19, the possibilities of treating obesity using a combined preparation containing sibutramine and metformin in one tablet, are discussed.
About the Authors
T. Yu. Demidova
N.I. Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation
Russian Federation
Competing Interests:
Russian Federation
Tatiana Yu. Demidova, MD, PhD, Professor
Moscow
eLibrary SPIN: 9600-9796
Competing Interests:
Демидова Т.Ю. — лектор, участник экспертных советов, клинических исследований компаний Astra Zeneca, Novo Nordisk, Sanofi, Novartis, Boehringer Ingelheim, Takeda, Berlin Chemi.
E. I. Volkova
N.I. Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation
Еkaterina I. Volkova, resident
Moscow
E. Yu. Gritskevich
N.I. Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation
Еlena Yu. Grickevich, MD
109263, Moscow, st. Shkuleva, 4/1
eLibrary SPIN: 4125-2055
References
1. Yumuk V, Tsigos C, Fried M, et al. European Guidelines for Obesity Management in Adults. Nerurkar P V., ed. Obes Facts. 2015;8(6):402-424. doi: https://doi.org/10.1159/000442721
2. WHO. Obesity and overweight. Available from: https://www.who.int/ru/news-room/fact-sheets/detail/obesity-and-overweight
3. Muromtseva GA, Kontsevaya AV, Konstantinov VV, et al. The prevalence of non-infectious diseases risk factors in russian population in 2012-2013 years. The results of ECVD-RF. Cardiovascular Therapy and Prevention. 2014;13(6):4-11. (In Russ.) doi: https://doi.org/10.15829/1728-8800-2014-6-4-11
4. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China. JAMA. 2020;323(13):1239. doi: https://doi.org/10.1001/jama.2020.2648
5. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054-1062. doi: https://doi.org/10.1016/S0140-6736(20)30566-3
6. Ortega FB, Lavie CJ, Blair SN. Obesity and Cardiovascular Disease. Circ Res. 2016;118(11):1752-1770. doi: https://doi.org/10.1161/CIRCRESAHA.115.306883
7. Dzau VJ, Antman EM, Black HR, et al. The Cardiovascular Disease Continuum Validated: Clinical Evidence of Improved Patient Outcomes. Circulation. 2006;114(25):2850-2870. doi: https://doi.org/10.1161/CIRCULATIONAHA.106.655688
8. Petrilli CM, Jones SA, Yang J, et al. Factors associated with hospitalization and critical illness among 4,103 patients with Covid-19 disease in New York City. medRxiv. January 2020:2020.04.08.20057794. doi: https://doi.org/10.1101/2020.04.08.20057794
9. Garg S, Kim L, Whitaker M, et al. Hospitalization Rates and Characteristics of Patients Hospitalized with LaboratoryConfirmed Coronavirus Disease 2019 — COVID-NET, 14 States, March 1–30, 2020. MMWR Morb Mortal Wkly Rep. 2020;69:458-464. doi: https://dx.doi.org/10.15585/mmwr.mm6915e3
10. Deng S-Q, Peng H-J. Characteristics of and Public Health Responses to the Coronavirus Disease 2019 Outbreak in China. J Clin Med. 2020;9(2):575. doi: https://doi.org/10.3390/jcm9020575
11. Simonnet A, Chetboun M, Poissy J, et al. High Prevalence of Obesity in Severe Acute Respiratory Syndrome Coronavirus‐2 (SARS‐CoV‐2) Requiring Invasive Mechanical Ventilation. Obesity. 2020;28(7):1195-1199. doi: https://doi.org/10.1002/oby.22831
12. Samad F, Ruf W. Inflammation, obesity, and thrombosis. Blood. 2013;122(20):3415-3422. doi: https://doi.org/10.1182/blood-2013-05-427708
13. Maffetone PB, Laursen PB. The Perfect Storm: Coronavirus (Covid-19) Pandemic Meets Overfat Pandemic. Front Public Heal. 2020;8(20):3415-3422. doi: https://doi.org/10.3389/fpubh.2020.00135
14. Sattar N, McInnes IB, McMurray JJV. Obesity Is a Risk Factor for Severe COVID-19 Infection. Circulation. 2020;142(1):4-6. doi: https://doi.org/10.1161/CIRCULATIONAHA.120.047659
15. Mraz M, Haluzik M. The role of adipose tissue immune cells in obesity and low-grade inflammation. J Endocrinol. 2014;222(3):R113-R127. doi: https://doi.org/10.1530/JOE-14-0283
16. Qin C, Zhou L, Hu Z, et al. Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China. Clin Infect Dis. 2020;71(15):762-768. doi: https://doi.org/10.1093/cid/ciaa248
17. Kern L, Mittenbühler M, Vesting A, et al. Obesity-Induced TNFα and IL-6 Signaling: The Missing Link between Obesity and Inflammation — Driven Liver and Colorectal Cancers. Cancers (Basel). 2018;11(1):24. doi: https://doi.org/10.3390/cancers11010024
18. Trim W, Turner JE, Thompson D. Parallels in Immunometabolic Adipose Tissue Dysfunction with Ageing and Obesity. Front Immunol. 2018;9(1):24. doi: https://doi.org/10.3389/fimmu.2018.00169
19. Yiu HH, Graham AL, Stengel RF. Dynamics of a Cytokine Storm. Dehmer M, ed. PLoS One. 2012;7(10):e45027. doi: https://doi.org/10.1371/journal.pone.0045027
20. de Lucena TMC, da Silva Santos AF, de Lima BR, et al. Mechanism of inflammatory response in associated comorbidities in COVID-19. Dehmer M, ed. Diabetes Metab Syndr Clin Res Rev. 2020;14(4):597-600. doi: https://doi.org/10.1016/j.dsx.2020.05.025
21. Ryan PM, Caplice NM. Is Adipose Tissue a Reservoir for Viral Spread, Immune Activation, and Cytokine Amplification in Coronavirus Disease 2019? Obesity. 2020;28(7):1191-1194. doi: https://doi.org/10.1002/oby.22843
22. Chinese Clinical Trial Registry. Registration number: ChiCTR2000029765 — A multicenter, randomized controlled trial for the efficacy and safety of tocilizumab in the treatment of new coronavirus pneumonia (COVID-19). 2020 [cited 2020 06/04/2020]. Available from: http://www.chictr.org.cn/showproj.aspx?proj=49409
23. Wang W, Xu Y, Gao R, et al. Detection of SARS-CoV-2 in Different Types of Clinical Specimens. JAMA. 2020;28(7):1191-1194. doi: https://doi.org/10.1001/jama.2020.3786
24. Nishimura H, Itamura S, Iwasaki T, et al. Characterization of human influenza A (H5N1) virus infection in mice: neuro-, pneumoand adipotropic infection. J Gen Virol. 2000;81(10):2503-2510. doi: https://doi.org/10.1099/0022-1317-81-10-2503
25. Drucker DJ. Coronavirus Infections and Type 2 Diabetes— Shared Pathways with Therapeutic Implications. Endocr Rev. 2020;41(3):457-470. doi: https://doi.org/10.1210/endrev/bnaa011
26. Stefan N, Birkenfeld AL, Schulze MB, Ludwig DS. Obesity and impaired metabolic health in patients with COVID-19. Nat Rev Endocrinol. 2020;16(7):341-342. doi: https://doi.org/10.1038/s41574-020-0364-6
27. Pal R, Bhadada SK. COVID-19 and diabetes mellitus: An unholy interaction of two pandemics. Dehmer M, ed. Diabetes Metab Syndr Clin Res Rev. 2020;14(4):513-517. doi: https://doi.org/10.1016/j.dsx.2020.04.049
28. Di Renzo L, Gualtieri P, Pivari F, et al. Eating habits and lifestyle changes during COVID-19 lockdown: an Italian survey. Dehmer M, ed. J Transl Med. 2020;18(1):229. doi: https://doi.org/10.1186/s12967-020-02399-5
29. Yumuk V, Tsigos C, Fried M, et al. European Guidelines for Obesity Management in Adults. Dehmer M, ed. Obes Facts. 2015;8(6):402-424. doi: https://doi.org/10.1159/000442721
30. Dedov II, Mel’nichenko GA, Shestakova MV, et al. Russian national clinical recommendations for morbid obesity treatment in adults. 3rd revision (Morbid obesity treatment in adults). Obesity and Metabolism. 2018;15(1):53-70 (In Russ.) doi: https://doi.org/10.14341/omet2018153-70
31. Wilding JPH, Overgaard RV, Jacobsen LV, et al. Exposure-response analyses of liraglutide 3.0 mg for weight management. Diabetes, Obes Metab. 2016;18(5):491-499. doi: https://doi.org/10.1111/dom.12639
32. Dedov II, Troshina EA, Mazurina NV, et al. The role of neurotransmitters in regulation of energy homeostasis and possibility of drug correction of its disturbances in obesity. Obesity and Metabolism. 2016;13(1):9-15. (In Russ.) doi: https://doi.org/10.14341/omet201619-15
33. Romantsova TI. Sibutramine: efficacy and safety of prescribing in routine clinical practice. Obesity and Metabolism. 2016. — Т. 13. — №1. — С. 9-15. 2015;12(3):18-24. (In Russ.) doi: https://doi.org/10.14341/omet2015318-24
34. James WPT, Caterson ID, Coutinho W, et al. Effect of Sibutramine on Cardiovascular Outcomes in Overweight and Obese Subjects. N Engl J Med. 2010;363(10):905-917. doi: https://doi.org/10.1056/NEJMoa1003114
35. Seimon R V, Espinoza D, Ivers L, et al. Changes in body weight and blood pressure: paradoxical outcome events in overweight and obese subjects with cardiovascular disease. Int J Obes. 2014;38(9):1165-1171. doi: https://doi.org/10.1038/ijo.2014.2
36. Caterson ID, Finer N, Coutinho W, et al. Maintained intentional weight loss reduces cardiovascular outcomes: results from the Sibutramine Cardiovascular OUTcomes (SCOUT) trial. Diabetes, Obes Metab. 2012;14(6):523-530. doi: https://doi.org/10.1111/j.1463-1326.2011.01554.x
37. Hayes JF, Bhaskaran K, Batterham R, et al. The effect of sibutramine prescribing in routine clinical practice on cardiovascular outcomes: a cohort study in the United Kingdom. Int J Obes. 2015;39(9):1359-1364. doi: https://doi.org/10.1038/ijo.2015.86
38. Ametov A.S. Otchet o programme VESNA. Effektivnoe lechenie ozhireniya-put’ bor’by s epidemiei diabetes mellitus. Endokrinologiya: Novosti. Mneniya. Obuchenie. 2013;(2):12-16. (In Russ.)
39. Dedov II, Mel’nichenko GA, Romantsova TI. The strategy of obesity management: the results of All-Russian observational program “Primavera.” Obesity and Metabolism. 2016;13(1):36-44. (In Russ.) doi: https://doi.org/10.14341/omet2016136-44
40. Dedov II, Romantsova TI, Shestakova MV. Rational approach to patients treatment with type 2 diabetes and obesity: results of the AllRussian observational program «AURORA». Obesity and Metabolism. 2019;15(4):48-58. (In Russ.) doi: https://doi.org/10.14341/omet10076
41. Demidova TYu, Kishkovich YuS. Prediabet: sovremennoe sostoyanie problemy i vozmozhnosti korrektsii. RMZh. Meditsinskoe obozrenie. 2019;10(2):60-67. (In Russ.)
42. Shen X, Fan B, Hu X, et al. Metformin Reduces LipotoxicityInduced Meta-Inflammation in β -Cells through the Activation of GPR40-PLC-IP3 Pathway. J Diabetes Res. 2019;2019(4):1-16. doi: https://doi.org/10.1155/2019/7602427
43. Hundal RS, Krssak M, Dufour S, et al. Mechanism by which metformin reduces glucose production in type 2 diabetes. Diabetes. 2000;49(12):2063-2069. doi: https://doi.org/10.2337/diabetes.49.12.2063
44. Zilov AV, Abdelaziz SI, AlShammary A, et al. Mechanisms of action of metformin with special reference to cardiovascular protection. Diabetes Metab Res Rev. 2019;35(7):2063-2069. doi: https://doi.org/10.1002/dmrr.3173
45. Malhotra A, Hepokoski M, McCowen KC, Y-J Shyy J. ACE2, Metformin, and COVID-19. iScience. 2020;23(9):101425. doi: https://doi.org/10.1016/j.isci.2020.101425
46. Jian M-Y, Alexeyev MF, Wolkowicz PE, et al. Metforminstimulated AMPK-α1 promotes microvascular repair in acute lung injury. Am J Physiol Cell Mol Physiol. 2013;305(11):L844-L855. doi: https://doi.org/10.1152/ajplung.00173.2013
47. Shang F, Zhang J, Li Z, et al. Cardiovascular Protective Effect of Metformin and Telmisartan: Reduction of PARP1 Activity via the AMPK-PARP1 Cascade. Huang Y, ed. PLoS One. 2016;11(3):e0151845. doi: https://doi.org/10.1371/journal.pone.0151845
48. Tsaknis G, Siempos II, Kopterides P, et al. Metformin attenuates ventilator-induced lung injury. Crit Care. 2012;16(4):R134. doi: https://doi.org/10.1186/cc11439
49. Jo YS, Choi SM, Lee J, et al. Effect of Preadmission Metformin Use on Clinical Outcome of Acute Respiratory Distress Syndrome among Critically Ill Patients with Diabetes. Tuberc Respir Dis (Seoul). 2017;80(3):296. doi: https://doi.org/10.4046/trd.2017.80.3.296
50. Luo P, Qiu L, Liu Y, et al. Metformin Treatment Was Associated with Decreased Mortality in COVID-19 Patients with Diabetes in a Retrospective Analysis. Am J Trop Med Hyg. 2020;103(1):69-72. doi: https://doi.org/10.4269/ajtmh.20-0375
51. Malin SK, Kashyap SR. Effects of metformin on weight loss. Curr Opin Endocrinol Diabetes Obes. 2014;21(5):323-329. doi: https://doi.org/10.1097/MED.0000000000000095
52. Ametov AS, P’yanykh OP, Nevol’nikova AO. Sovremennye vozmozhnosti upravleniya metabolicheskim zdorov’em u patsientov s ozhireniem i narusheniyami uglevodnogo obmena. Endokrinologiya: novosti, mneniya, obuchenie. 2020;9(1):17-26. (In Russ.) doi: https://doi.org/10.33029/2304-9529-2020-9-1-17-26
Supplementary files
|
|
1. Figure 1. Deviation of the amount of adipose tissue from the norm increases the risk of infection and complications in the presence of COVID-19. | |
| Subject | ||
| Type | Исследовательские инструменты | |
View
(327KB)
|
Indexing metadata ▾ | |
|
|
2. Figure 2. Obesity and virus-Induced hyperinflammation. | |
| Subject | ||
| Type | Исследовательские инструменты | |
View
(344KB)
|
Indexing metadata ▾ | |
|
|
3. Figure 3. Mutual aggravating effects of COVID-19, obesity and carbohydrate metabolism disorders. | |
| Subject | ||
| Type | Исследовательские инструменты | |
View
(406KB)
|
Indexing metadata ▾ | |
Review
For citations:
Demidova T.Yu., Volkova E.I., Gritskevich E.Yu. Peculiarities of the COVID-19 course and consequences in overweight and obese patients. Lessons from the current pandemic. Obesity and metabolism. 2020;17(4):375-384. (In Russ.) https://doi.org/10.14341/omet12663
Views:
5914
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
